Journal
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
Volume 33, Issue 2, Pages 291-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.hoc.2018.12.005
Keywords
Immunotherapy; Predictive and prognostic biomarkers; Checkpoint inhibition; Immunohistochemistry
Categories
Funding
- NCATS NIH HHS [TL1 TR001875, UL1 TR001873] Funding Source: Medline
- NCI NIH HHS [UH2 CA218149] Funding Source: Medline
- NHLBI NIH HHS [T35 HL007616] Funding Source: Medline
- FDA HHS [R01 FD006108] Funding Source: Medline
Ask authors/readers for more resources
Immunotherapy has drastically improved the prognosis of many patients with cancer, but it can also lead to severe immune-related adverse events. Biomarkers, which are molecular markers that indicate a patient's disease outcome or a patient's response to treatment, are therefore crucial to helping clinicians weigh the potential benefits of immunotherapy against its potential toxicities. Immunohistochemistry (IHC) has thus far been a powerful technique for discovery and use of biomarkers such as CD8(+) tumor infiltrating lymphocytes. However, IHC has limited reproducibility. Thus, if more IHC-based biomarkers are to reach the clinic, refinement of the technique using multiplexing or automation is key.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
